Dr. Marcelo Pomeranz

Associate
mpomeranz@cooley.com
Full contact info

I combine deep legal and technical knowledge to arrive at creative solutions for emerging therapeutic and biotechnology clients.

About Marcelo

Marcelo focuses his practice on the development and execution of worldwide intellectual property strategies for biotech and pharmaceutical companies. He has extensive experience securing, defending and challenging patents to provide clients with the necessary protection and freedom to operate to monetize their inventions. Marcelo has counseled many prominent life sciences companies and investors on US Food and Drug Administration exclusivity strategies and helped emerging companies and investors navigate diligence matters in venture capital, M&A and public company offerings. He has also supported patent litigation in federal courts and inter partes review challenges before the US Patent and Trademark Office.

View full bio

Passions

Traveling

Fitness

Scuba diving

Surfing

Experience

Cerberus Ventures Leads Syntis Bio’s $38 Million Financing

Cerberus Ventures Leads Syntis Bio’s $38 Million Financing

July 1, 2025

Cooley advised Cerberus Ventures, a venture fund established in 2023 to invest in early-stage companies in sectors important to government and innovators, as lead investor in Syntis Bio’s $38 million financing. Partners Matthew Bartus, Marc Recht and Christophe Beauduin led the Cooley team advising Cerberus Ventures.

Related contacts

Matthew Bartus
Partner, San Francisco
Marc Recht
Partner, Boston
Christophe Beauduin
Partner, New York
Andrew Leonard
Associate, Washington, DC
Alex Abelson
Associate, New York
Dr. Marcelo Pomeranz
Associate, San Diego
Michael Fernando
Associate, London

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences

Cooley advises Provivi on $45.5M Series C-2 Round

Cooley advises Provivi on $45.5M Series C-2 Round

January 8, 2021

Cooley advised emerging crop protection company Provivi on its $45.5 million series C-2 financing round led by Vivo Capital, with participation from returning shareholders. Provivi has developed a truly disruptive technological platform that enables the scalable production of environmentally friendly insect pheromone products. These products are able to naturally disrupt the mating cycle of insect pests and reduce the current overreliance upon non-sustainable synthetic insecticides. "The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico," said Dr. Pedro Coelho, cofounder and CEO of Provivi.

Related contacts

Dr. Chris Holly
Partner, Washington, DC
Rachel Proffitt
Partner and Chief Executive Officer, San Francisco
Julia Gage
Associate, San Francisco
Ron Metzger
Paralegal Specialist, San Francisco
Dr. Marcelo Pomeranz
Associate, San Diego

Cooley secures key patent on agricultural disease-fighting bacterium for Montana State University's College of Agriculture

Cooley secures key patent on agricultural disease-fighting bacterium for Montana State University's College of Agriculture

December 13, 2018

The patented process uses a naturally occurring BmJ bacterium to activate the natural immune defenses of plants against bacterial, viral, and fungal diseases. The BmJ bacterium was originally isolated from the healthy leaves of beet plants in an otherwise disease-ridden sugar beet field. Dr. Barry Jacobsen, a professor of plant sciences and plant pathology, discovered BmJ's role in natural plant resistance, and played a key role in developing the bacterium into a commercial product.

This novel treatment is expected to provide farmers with an effective and natural alternative to traditional chemical crop treatments. The patented BmJ spray was recently approved by the EPA for use in the United States, and is expected to become available soon to farmers all over the world through MSU's partnership with Certis USA.

Cooley attorneys were instrumental in counseling MSU throughout the patent procurement and licensing phases of BmJ's development. Cooley is now home to the largest life sciences patent practice in the US, and is a leader in working with universities, as well as startup and established companies in developing next-generation Ag-Biotech solutions

Related contacts

Dr. Chris Holly
Partner, Washington, DC
Dr. Marcelo Pomeranz
Associate, San Diego

Related Practices & Industries

Patent Counseling and Prosecution – Agricultural Science
Life Sciences

Admissions and credentials

California

District of Columbia Bar Association

Registered to practice before the United States Patent and Trademark Office (USPTO)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.